No matches
Pulmonology

Corticosteroids in Asthma Management

This infographic illustrates the ongoing burden associated with maintenance oral corticosteroid (OCS) use and high-dose inhaled corticosteroids (ICS) in asthma, including the clinical impact of corticosteroid exposure, supporting evidence, and the importance of considering corticosteroid burden in asthma management.

Related resources

Airway Hyperresponsiveness In Asthma Is Mainly Driven By Components Of Type 2 Inflammation

Airway Hyperresponsiveness In Asthma Is Mainly Driven By Components Of Type 2 Inflammation

interactivity
ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma

ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma

Podcast

Learning objectives

  • Recognize the burden associated with OCS in asthma management
  • Understand the risks associated with higher-dose ICS exposure in asthma management
Tags
asthma
MAT-GLB-2604423 - 1.0 - 09/2026

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: FranceChange country/region